Alkem Labs launches generic Anti-Epileptic drug in India

Alkem Labs launches generic Anti-Epileptic drug in India

212
Medicine
Picture: Pixabay

Last Updated on March 17, 2021 by The Health Master

Drug firm Alkem Laboratories on Monday said it has launched a generic anti-epileptic drug in India to make epilepsy treatment more accessible and affordable. The drug has been launched under the brand name ‘Brivasure‘.

To read more about Alkem, click here

The company, “has launched the drug in the market at price, Brivasure 25mg – Rs 79.50/strip, Brivasure 50mg – Rs 148.50/strip, Brivasure 75mg – Rs 230/strip, Brivasure 100mg – Rs 295/strip, post patent expiry of innovator product, of Brivaracetam as on February 21, 2021,” Alkem Labs said in a BSE filing.

“With the launch of Brivasure, we aim to make the treatment of Epilepsy easily accessible to the patients at affordable pricing,” Alkem Laboratories, Chronic Business President Yogesh Kaushal said.

Shares of Alkem Laboratories Ltd settled at Rs 2,714.65 per scrip on BSE, down 2.08 per cent over previous close.


Also read:

Pharma Companies recall these drugs in US

AstraZeneca gets DCGI approval for Osimertinib tablets

Lupin launches generic Nitazoxanide tablets

Dr Reddy’s gets 3 observations from USFDA for US-based API plant

World’s most expensive drug, costs ₹18 crore per dose

NATCO gets USFDA nod for Breast Cancer treatment drug

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner